A team of Swedish researchers has received $3.3 million to develop a new nanotechnology platform for detecting blood-borne markers in lung and breast cancer.
QuantuMDx will use Scienion's ultra-low-volume liquid handling technologies in its Q-Poc handheld molecular diagnostic device.
The team showed the approach could successfully monitor cytokines in infants after heart surgery, and is involved now in a larger clinical study expanding this research.
Cambridge Bioscience will be NanoInk's exclusive distributor in the UK and Ireland, NanoInk said this week.
NanoInk has tapped two distributors to sell its nanofabrication platforms in the Asia Pacific region.
Avantra Biosciences' Rapid Assay Prototyping Service, NanoInk's NanoArray Assay System
Roughly 40 percent of the funding will go toward NanoInk's BioDiscovery division, where it will be used to build out the company's sales and marketing organization and fund development of new products based on its protein nanoarray platform.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.
Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.
Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.